China Tracker - Safety/Risk Model (Stage One) for Skystar Bio-Pharmaceutical (SKBI)

 Skystar Bio-Pharmaceutical
 Going Public
Market Segment:
Going Public: 2005-11-07Reverse Merger
 Auditor
Auditor: Crowe Horwath
Number of Auditors (since Jan 1, 2009): 2 
Auditor Resignations (since Jan 1, 2009): none 
 Internal Controls
Internal Controls (Management): not effective
Internal Controls (Audit): not performed 
Senior Management Changes (since Jan 1, 2009): 1 
Number of CFOs (since Jan 1, 2009): 2 
CFO Resignations (since Jan 1, 2009): 1
Main Shareholder (Weibing Lu): Chairman, CEO 
Ownership Percentage: 13.10% 
 Analyst Coverage
Total Coverage: 3 Analyst(s) 
Tier 1 Firms: 0 Analyst(s) 
Tier 2/3 Firms: 2 Analyst(s) 
 Indicators
New Shares / Dilution (TTM): 0.02 million0.30%
Short Interest (2010-06-30): 0.14 million2.32% 
Account Receivables (MRQ): $3.98 million5,555.86%
 Recent Events
Delinquent with SEC Filings: NO 
Short Seller Attacks (Corporate Governance): YES
Detailed Fraud Allegations: NO 
 
 Auditor History (since January 1, 2009)
2010-12-13Crowe HorwathAppointment
2010-12-13Frazer FrostDismissal
 Senior Management Trail (since January 1, 2009)
2010-04-16Michael Hongjie LanCFOAppointment
2010-04-16Bennet P. TchaikovskyCFOResignation
SKBI
Agriculture
SAFETY/RISK SCORE
42%
HIGH RISK
Detailed Score: 356.25/830
Current Price:  $0.01
F10k Day (2007-08-13): -99.92%$12.00
2009 Close: -99.91%$10.10
2010 Close: -99.90%$9.73
High (2012-02-15): -99.70%$3.24
Low (2012-09-21): -99.35%$1.52
Exchange: OBB
Market Capitalization: 0.07 mill
Total Shares: 7.16 mill
Float: n/a
Last Quarter: 2011-06-30
Revenue (MRQ): 9.10 mill
Net Income (MRQ): 1.15 mill
Op. Cash Flow (MRQ): 2.37 mill
all financial data provided without warranty